Clemens Mellink

2.1k total citations
30 papers, 889 citations indexed

About

Clemens Mellink is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Clemens Mellink has authored 30 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 10 papers in Molecular Biology and 9 papers in Hematology. Recurrent topics in Clemens Mellink's work include Chronic Lymphocytic Leukemia Research (14 papers), Acute Myeloid Leukemia Research (5 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Clemens Mellink is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Acute Myeloid Leukemia Research (5 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Clemens Mellink collaborates with scholars based in Netherlands, United States and Canada. Clemens Mellink's co-authors include Aggie Nieuwint, Wim L.J. van Putten, Dimitri Breems, Bob Löwenberg, Klasien B.J. Gerssen‐Schoorl, Martine Jotterand, Georgine E. de Greef, Anne Hagemeijer, Shama L. van Zelderen‐Bhola and H. Berna Beverloo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncogene.

In The Last Decade

Clemens Mellink

29 papers receiving 876 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clemens Mellink Netherlands 13 494 310 275 174 152 30 889
Sabrina Tosi United Kingdom 20 578 1.2× 550 1.8× 180 0.7× 229 1.3× 108 0.7× 52 1.1k
Anna Aventı́n Spain 20 495 1.0× 372 1.2× 317 1.2× 185 1.1× 147 1.0× 58 938
Marie Jarošová Czechia 17 354 0.7× 264 0.9× 301 1.1× 108 0.6× 95 0.6× 87 766
Françoise Brizard France 14 343 0.7× 278 0.9× 252 0.9× 87 0.5× 87 0.6× 33 680
Sandra Weißmann Germany 10 525 1.1× 396 1.3× 317 1.2× 252 1.4× 91 0.6× 28 861
Mauro Nanni Italy 16 456 0.9× 402 1.3× 294 1.1× 112 0.6× 103 0.7× 43 804
Marie‐Josée Le Bris France 18 551 1.1× 420 1.4× 235 0.9× 245 1.4× 48 0.3× 55 986
Nicolas Duployez France 17 621 1.3× 375 1.2× 303 1.1× 190 1.1× 93 0.6× 67 950
Odile Maarek France 13 645 1.3× 352 1.1× 411 1.5× 120 0.7× 120 0.8× 24 1.0k
Margit König Austria 19 667 1.4× 412 1.3× 137 0.5× 541 3.1× 108 0.7× 43 1.1k

Countries citing papers authored by Clemens Mellink

Since Specialization
Citations

This map shows the geographic impact of Clemens Mellink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clemens Mellink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clemens Mellink more than expected).

Fields of papers citing papers by Clemens Mellink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clemens Mellink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clemens Mellink. The network helps show where Clemens Mellink may publish in the future.

Co-authorship network of co-authors of Clemens Mellink

This figure shows the co-authorship network connecting the top 25 collaborators of Clemens Mellink. A scholar is included among the top collaborators of Clemens Mellink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clemens Mellink. Clemens Mellink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology. 41(S2). 239–242. 8 indexed citations
2.
Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL). HemaSphere. 7(S3). e492813f–e492813f. 11 indexed citations
3.
Thijssen, Rachel, Simon P. Mackay, Julie Dubois, et al.. (2022). JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL. Molecular Oncology. 17(6). 1112–1128. 15 indexed citations
4.
Bolen, Christopher R., John F. Seymour, Peter Hillmen, et al.. (2019). IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY. Hematological Oncology. 37(S2). 106–108. 3 indexed citations
5.
Hansen, Marten, Eszter Varga, Clemens Mellink, et al.. (2017). Generation and characterization of a human iPSC line SANi005-A containing the gray platelet associated heterozygous mutation p.Q287* in GFI1B. Stem Cell Research. 25. 34–37. 2 indexed citations
6.
Hansen, Marten, Eszter Varga, Clemens Mellink, et al.. (2017). Generation and characterization of human iPSC lines SANi001-A and SANi002-A from mobilized peripheral blood derived megakaryoblasts. Stem Cell Research. 25. 42–45.
7.
Hansen, Marten, Eszter Varga, Nelleke P.M. Brouwer, et al.. (2016). Generation and characterization of human iPSC line MML-6838-Cl2 from mobilized peripheral blood derived megakaryoblasts. Stem Cell Research. 18. 26–28. 11 indexed citations
8.
Andel, Harmen van, Kinga A. Kocemba‐Pilarczyk, Clemens Mellink, et al.. (2016). Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene. 36(15). 2105–2115. 41 indexed citations
9.
Krijgsman, Oscar, Hendrik F. van Essen, Paul P. Eijk, et al.. (2012). Detection limits of DNA copy number alterations in heterogeneous cell populations. Cellular Oncology. 36(1). 27–36. 16 indexed citations
10.
Santos, Joana, Nuno Cerveira, Susana Bizarro, et al.. (2009). Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. Leukemia Research. 34(5). 615–621. 16 indexed citations
11.
Cerveira, Nuno, Joana Santos, Susana Bizarro, et al.. (2009). Both SEPT2 and MLL are down-regulated in MLL-SEPT2therapy-related myeloid neoplasia. BMC Cancer. 9(1). 147–147. 10 indexed citations
12.
Nordkamp, Louise R.A. Olde, Clemens Mellink, C. Ellen van der Schoot, & Henk van den Berg. (2009). Karyotyping, FISH, and PCR in Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 31(12). 930–935. 22 indexed citations
13.
Gunn, Shelly, M.H. Afif, M. Gorre, et al.. (2008). Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia. Journal of Molecular Diagnostics. 10(5). 442–451. 56 indexed citations
14.
Gunn, Shelly, Lynn L. Barron, M. Gorre, et al.. (2008). Array CGH Analysis of Chronic Lymphocytic Leukemia Reveals Frequent Cryptic Monoallelic and Biallelic Deletions of Chromosome 22q11.. Blood. 112(11). 1050–1050. 2 indexed citations
15.
Gunn, Shelly, et al.. (2008). The HemeScan test for genomic prognostic marker assessment in chronic lymphocytic leukemia. Expert Opinion on Medical Diagnostics. 2(6). 731–740. 2 indexed citations
16.
Mellink, Clemens, et al.. (2004). Physical Localization of 5S rRNA Genes in the Pig by Fluorescence in Situ Hybridization. Hereditas. 124(1). 95–97. 11 indexed citations
17.
Mellink, Clemens, et al.. (2004). SBDS mutations and isochromosome 7q in a patient with Shwachman-Diamond syndrome: no predisposition to malignant transformation?. Cancer Genetics and Cytogenetics. 154(2). 144–149. 12 indexed citations
18.
Haralambieva, Eugenia, Ed Schuuring, Stefano Rosati, et al.. (2004). Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: Validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes and Cancer. 40(1). 10–18. 42 indexed citations
19.
Leeksma, Onno, Tanja A.E. van Achterberg, Jiro Toshima, et al.. (2002). Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. European Journal of Biochemistry. 269(10). 2546–2556. 75 indexed citations
20.
Hoovers, J.M.N., Clemens Mellink, & N. J. Leschot. (1999). [Fluorescence in situ hybridization in the study of chromosomal abnormalities].. PubMed. 143(45). 2265–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabrina Tosi Breakdown of academic impact, for papers by Anna Aventı́n Breakdown of academic impact, for papers by Marie Jarošová Breakdown of academic impact, for papers by Françoise Brizard Breakdown of academic impact, for papers by Sandra Weißmann Breakdown of academic impact, for papers by Mauro Nanni Breakdown of academic impact, for papers by Marie‐Josée Le Bris Breakdown of academic impact, for papers by Nicolas Duployez Breakdown of academic impact, for papers by Odile Maarek Breakdown of academic impact, for papers by Margit König
Rankless by CCL
2026